Tirzepatide is a synthetic peptide that functions as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This unique “twincretin” mechanism has been studied extensively in metabolic research for its effects on glucose control, insulin sensitivity, and weight regulation.
A single-component research material supplied for controlled research environments. Suitable for studies involving GLP-1 receptor–related pathway characterization and method development in model systems.
Composition
-
GLP-1 T: 10 mg
-
Appearance: lyophilized powder in a sealed research vial
Research Focus (non-clinical)
-
Peptide identity and purity assessment via HPLC/LC-MS
-
Assay development and calibration for quantitative analysis of GLP-1 receptor–related models
-
Chromatographic method optimization for impurity profiling and peak resolution
-
Stability characterization of a lyophilized peptide under laboratory storage conditions
Documentation
-
Lot-specific COA available (HPLC/LC-MS)
-
Batch and lot traceability
Important Notice
-
For research use only
-
Not for human consumption
-
Not intended to diagnose, treat, cure, or prevent any disease
Quality & Manufacturing
-
Lot-specific COA (HPLC/LC-MS) with verification key
-
Third-party verification link provided per lot (Janoshik)
-
Lyophilized for transit stability; batch traceable
-
Tamper-evident seal; lot & test date on each vial
-
No MOQ for online orders
-
Bulk orders for physical locations start at 25-unit minimum
Specifications
-
Form: Lyophilized powder
-
Content: 10mg per vial
-
Purity: ≥99% (HPLC verified)
-
Storage: Store at −20°C; reconstituted solutions stable for short-term refrigerated use
-
Appearance: White/off-white powder
Research Applications
-
Investigations into glucose regulation and incretin pathways
-
Studies on energy balance, appetite, and weight modulation
-
Preclinical models of obesity, diabetes, and metabolic syndrome
Key Notes
-
Tirzepatide has shown significant reductions in HbA1c and body weight in clinical studies.
-
Its dual GIP/GLP-1 agonist activity differentiates it from GLP-1-only peptides such as semaglutide.
-
Research continues into cardiovascular and long-term metabolic outcomes.
Important Disclaimer
This material is provided for laboratory research use only. It is not intended for human consumption, medical, or veterinary use. All purchasers must be qualified researchers or institutions.
